参考来源: 1.Eylea® (aflibercept) Injection approved as the first pharmacologic treatment for preterm infants with retinopathy of prematurity (ROP) by the FDA. News release. Regeneron Pharmaceuticals, Inc. February 8, 2023. Accessed Febr...
Regeneron Pharmaceuticals(再生元)于2023年2月8日宣布美国食品药品监督管理局(FDA)已批准EYLEA(aflibercept)注射液治疗早产儿视网膜病变(ROP)。 EYLEA是由Regeneron和拜耳联合开发的一种VEGF抑制剂,被配制成用于眼部的注射剂。它旨在通过阻断VEGF-A和胎盘生长因子(PLGF),即参与眼部血管生成的两种生长因子,来阻止新血管的...
EYLEA (aflibercept) Injection as First-line Treatment in Wet Age-related Macular Degenerationdoi:10.1097/01.iae.0000754904.61893.77EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients...
参考来源：‘EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-relat...
英文名称:Aflibercept Intravitreous Injection 商品名称:艾力雅/Eylea 【成分】 活性成份为阿柏西普。通过重组DNA技术由中国仓鼠卵巢(CHO)K1细胞生产的融合蛋白,该融合蛋白是由人血管内皮生长因子受体(VEGFR)胞外结构域(即VEGFR1 Ig2区和VEGFR2 Ig3区)与人IgG1的Fc结构域融合后形成的同源二聚体糖蛋白。
Eylea may cause an increase in thepressure of the fluids inside the eye(intraocular pressure), usually within 60 minutes of an intravitreal injection. Temporary visual disturbancesmay occur following an intravitreal injection with Eylea. Do not drive or operate machinery until your vision recovers. ...
To visit the Global EYLEA® 8mg website, please confirm from the following options below: I am a Health Care Professional I am a caregiver/Other This website contains information onEYLEA® 8mg(aflibercept 114.3 mg/mL solution for injection) which is based on the Summary of Product Character...
原文出处:EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得...
参考资料:EYLEA®(AFLIBERCEPT)INJECTION APPROVED AS THE FIRST PHARMACOLOGIC TREATMENT FOR PRETERM INFANTS WITH RETINOPATHY OF PREMATURITY(ROP)BY THE FDA from https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-approved-first-pharmacologic...
Syringes prefilled with aflibercept by the manufacturer may cause elevated intraocular pressure (IOP) after intravitreal injection, the European Medicines Agency (EMA) is warning. The agency has received a "higher-than-expected proportion" of elevated IOP, its Pharmacovigilance Risk Assessment Committee ...